Search Results for: CDK6

148 interactions involving CDK6 - cyclin dependent kinase 6 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
H1-1 H1.1 linker histone, cluster member
  • Apoptosis induced DNA fragmentation
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
HGF hepatocyte growth factor
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • Drug-mediated inhibition of MET activation
  • Valproic acid
  • Heparin
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • ABT-510
  • Foretinib
HIF1A hypoxia inducible factor 1 subunit alpha
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Cellular response to hypoxia
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Expression
  • PTK6 promotes HIF1A stabilization
  • Neddylation
  • STAT3 nuclear events downstream of ALK signaling
  • Regulation of PD-L1(CD274) transcription
  • Carvedilol
  • Hydralazine
  • 2-Methoxyestradiol
  • ENMD-1198
  • PX-478
  • FG-2216
  • Vadadustat
HSF1 heat shock transcription factor 1
  • Regulation of HSF1-mediated heat shock response
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Aggrephagy
  • Mitochondrial unfolded protein response (UPRmt)
  • Bimoclomol
ISL1 ISL LIM homeobox 1
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Regulation of expression of SLITs and ROBOs
  • Cardiogenesis
KAT2A lysine acetyltransferase 2A
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HATs acetylate histones
  • Notch-HLH transcription pathway
  • B-WICH complex positively regulates rRNA expression
  • Ub-specific processing proteases
  • RNA Polymerase I Transcription Initiation
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Cardiogenesis
  • Formation of WDR5-containing histone-modifying complexes
  • Formation of paraxial mesoderm
  • Coenzyme A
KDELR2 KDEL endoplasmic reticulum protein retention receptor 2
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
KEAP1 kelch like ECH associated protein 1
  • Ub-specific processing proteases
  • Neddylation
  • Potential therapeutics for SARS
  • KEAP1-NFE2L2 pathway
  • Nuclear events mediated by NFE2L2
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Dimethyl fumarate
KIF26B kinesin family member 26B
  • COPI-dependent Golgi-to-ER retrograde traffic
  • Kinesins
KLF10 KLF transcription factor 10
LATS2 large tumor suppressor kinase 2
  • Signaling by Hippo
LPIN1 lipin 1
  • Synthesis of PC
  • Synthesis of PE
  • Depolymerization of the Nuclear Lamina
  • Triglyceride biosynthesis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
MAP2K3 mitogen-activated protein kinase kinase 3
  • Oxidative Stress Induced Senescence
  • activated TAK1 mediates p38 MAPK activation
  • Fostamatinib
  • Pimasertib
MAP2K5 mitogen-activated protein kinase kinase 5
  • Signalling to ERK5
  • Fostamatinib
  • Pimasertib
MAP3K5 mitogen-activated protein kinase kinase kinase 5
  • Oxidative Stress Induced Senescence
  • Oxidative Stress Induced Senescence
MAPK14 mitogen-activated protein kinase 14
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
MCM10 minichromosome maintenance 10 replication initiation factor
  • Activation of ATR in response to replication stress
  • Activation of the pre-replicative complex
MCM2 minichromosome maintenance complex component 2
  • Activation of ATR in response to replication stress
  • Unwinding of DNA
  • Assembly of the pre-replicative complex
  • Assembly of the pre-replicative complex
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • Switching of origins to a post-replicative state
  • Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
MEF2D myocyte enhancer factor 2D
  • Transcriptional activation of mitochondrial biogenesis
  • Myogenesis
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • Heme signaling
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
MET MET proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D mediated inhibition of cell attachment and migration
  • RAF/MAP kinase cascade
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • MECP2 regulates neuronal receptors and channels
  • Drug-mediated inhibition of MET activation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Sunitinib
  • K-252a
  • SGX-523
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • AMG-208
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Crizotinib
  • Cabozantinib
  • Capmatinib
  • Tivozanib
  • Fostamatinib
  • Tivantinib
  • Brigatinib
  • Amuvatinib
  • Tepotinib
  • Amivantamab
  • Cholangiocarcinoma
  • Gastric cancer
  • Renal cell carcinoma

Page 4 out of 8 pages